Harm Prevention

Clostridium Difficile Infection

Clostridium Difficile (C. Difficile) is a bacterial cause of diarrhea in hospitalized patients and in those who have been treated with prolonged antibiotics. It is characterized by watery diarrhea with dehydration and overwhelming abdominal sepsis and shock. The infection is hard to detect as it overlaps with many other causes of diarrhea and requires a high “index of suspicion” on the part of caregivers. Moreover, the bacteria that causes C. Difficile is resistant and hard to eradicate.
Clostridium Difficile Bacteria
A Clostridium Difficile Infection (CDI) causes significant risk of morbidity and increased costs for providers and the patients suffering from the infection. In a recent study conducted by the National Heart, Lung, and Blood Institute (NHLBI), the average hospital cost for CDI per case ranges from $9,000 to $11,500 and one in 11 patients over the age of 65 will die within a month of a CDI diagnosis. The total cost of U.S. healthcare for CDIs approaches $500 Million per year. And the average increase in length of stay directly attributed the infection varies widely between 3 and 21 days.
The Jvion Machine is equipped to identify patients at risk of developing a CDI during a hospital stay and deliver the personalized interventions that will prevent the infection. The machine incorporates the latest CDI research and clinical intelligence to pin point individuals on a risk trajectory toward a CDI while accounting for those asymptomatic patients who are nearly impossible to detect. The machine renders granular, patient-level propensity information that is customizable to a provider’s operational needs. The clinical actions enabled by the Jvion Machine empower care givers with the information they need to work collaboratively across functions to lower CDI rates and losses while improving health outcomes.

Conquering C. Difficile Associated Diarrhea with Probiotics

According to a recent study published by the Cochrane Library, the administration of probiotics to those at high-risk of developing C.difficile-associated diarrhea (CDAD) reduced a patient’s risk by 70%. This finding provides a low-cost, non-invasive option for reducing incidences of CDAD and the associated patient suffering. But the effectiveness of the treatment requires the early identification of at-risk patients who could benefit from probiotics. This is where the Jvion Machine is bridging the gap between new treatments and at-risk populations.

The patient population at high-risk of developing CDAD comprises 15% of the total patient population. These individuals are at more than 10% risk of developing the infection with an overall incidence rate of 1.7%.

The Jvion Machine is able to correctly identify 95% of all CDAD cases in the 15% of the population where the risk is greater than 10%. For a medium-size hospital with a patient population of 20,000, 3,000 patients would be at high-risk, and of those 323 would develop CDAD. If probiotics are administered to the high-risk population, it stands to reason that 226 or (70%) of these incidences could be prevented.

Probiotics cost $24 per patient. Using the Jvion Machine, we can target the administration of these probiotics to the 15% of the population at high-risk of an infection. The total spend of the intervention across all 3,000 patients comes to $72,000. The cost estimate per CDAD episode cited within the Cochrane study is $7,286. By preventing the anticipated 226 cases of CDAD, we would avoid $1,646,636 in costs. The total cost savings after accounting for the cost of treatment is $1,574,636. And this is all enabled by the ability to identify who is on a trajectory toward CDAD risk, providing the right information on the contributors to that risk, and enabling the clinical action that will lead to the best possible outcomes—in this case probiotics.


Jvion's Thinking Machine

We created a machine that thinks like a clinician. Here is how we did it.

Immerse Yourself in the Jvion Machine

Take just 2.5 minutes to dive into the world of prescriptive analytics for preventable harm.

The Jvion Machine in Action

See firsthand how the Jvion machine can help your patients and your organization.